胆管癌首个靶向治疗法-培米替尼

The first targeted therapy for cholangiocarcinoma -

On April 17, 2020, the U.S. Food and Drug Administration (FDA) officially announced the approval of the FGFR2 inhibitor pemetinib for the treatment of patients with previously treated advanced cholangiocarcinoma with FGFR2 gene fusion/rearrangement.

The approval of pemetinib was based on the clinical trial code-named FIGHT-202. The trial results showed that among 107 patients with FGFR2 fusion/rearrangement, all patients responded to the treatment. The overall response rate of pemetinib monotherapy was 36%, including 2.8% complete response and 33% partial response; the disease control rate was 82%. Median duration of response was 9.1 months; 63% of patients achieved response for 6 months or longer, and 18% maintained response for 12 months or longer.

Pemetinib was used for the second-line treatment of cholangiocarcinoma with FGFR2 fusion/rearrangement, and 82% of patients had tumors under control, and 33% of patients had significant tumor shrinkage or improvement. It is worth noting that the overall survival (OS) has not yet been reached at the time of data cutoff, but the median overall survival (OS) of pemetinib is 21.1 months. Studies have shown that the historical average survival time of patients with second- and third-line treatments in the past was 6-7 months. This means that the second-line treatment with pemetinib has extended the survival of patients by more than three times!

In addition, the researchers stated that there were no uncontrollable adverse reactions with pemetinib during the study, and the severity of most adverse events was grade 1 or 2.

The remarkable results achieved in the treatment of cholangiocarcinoma have encouraged researchers to study new drugs, and also confirmed that FGFR2 inhibitors indeed have a significant inhibitory effect on tumors.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: